楔形切除与肺叶切除用于伴隐匿淋巴结病变的临床IA期非小细胞肺癌
该研究基于美国国家癌症数据库,比较临床IA期(cT1N0)非小细胞肺癌隐匿性淋巴结转移(pN1/pN2)患者接受楔形切除与肺叶切除的长期生存。共5437例中93.5%接受肺叶切除、6.5%接受楔形切除;在隐匿pN1患者中肺叶切除与更优总生存相关,在pN2患者中未观察到显著差异;校正多变量分析显示肺叶切除仍与生存改善相关。
要点
- 临床IA期非小细胞肺癌隐匿pN1患者中,肺叶切除中位总生存70.0个月,楔形切除36.4个月(P < .001)。
- 隐匿pN2患者中,肺叶切除与楔形切除中位总生存48.2.1个月 vs 43.7个月(P = 0.24),原文数值写作48.2.1个月。
- 校正多变量分析显示肺叶切除仍与生存改善相关(校正风险比0.73;95%CI 0.60-0.89;P = .0016)。
核心结论
- 在临床IA期非小细胞肺癌伴隐匿淋巴结病变患者中,肺叶切除与生存改善相关。
- 这些数据可能有助于对非预期N1淋巴结升级患者决定是否行补充肺叶切除。
研究设计与样本
- 查询美国国家癌症数据库,纳入接受楔形切除或肺叶切除的临床IA期(cT1N0)非小细胞肺癌且病理升级为pN1/pN2的患者。
- 共纳入5437例临床IA期患者,其中3408例(62.7%)为隐匿pN1,2029例(37.3%)为隐匿pN2。
- 5437例中93.5%(5082例)接受肺叶切除,6.5%(355例)接受楔形切除。
- 采用逆概率治疗加权校正的Cox回归分析比较总生存。
主要发现
- 隐匿pN1患者中,肺叶切除中位总生存70.0个月(95%CI 66.6-77.4),楔形切除36.4个月(95%CI 24.2-45.6),P < .001。
- 隐匿pN2患者中,肺叶切除中位总生存48.2.1个月(95%CI 43.8-52.9),楔形切除43.7个月(95%CI 31.2-62.4),P = 0.24。
- 逆概率治疗加权校正多变量分析调整人口学、合并症、切缘状态及病理T和N分期后,肺叶切除仍与生存改善相关(校正风险比0.73;95%CI 0.60-0.89;P = .0016)。
临床怎么用
- 原文结论指出,这些数据可能有助于对非预期N1淋巴结升级患者决定是否行补充肺叶切除。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sublobar resection is increasingly performed for stage Ia non-small cell lung cancer, but pathologic lymph node upstaging remains a common clinical scenario. This study compares the long-term prognosis of patients with clinical stage Ia disease and occult lymph node disease undergoing wedge resection vs lobectomy. METHODS: The National Cancer Database was queried for patients treated with wedge resection or lobectomy for clinical stage Ia (cT1N0) non-small cell lung cancer and who were pathologically upstaged with either pN1/pN2 disease. Overall survival (OS) was compared by extent of resection using inverse probability treatment weighting-adjusted Cox regression analyses. RESULTS: Of 5437 clinical stage Ia patients included, 3408 (62.7%) were found to have occult pN1 and 2029 (37.3%) to have occult pN2. Of 5437 patients, 93.5% (5082) were treated with lobectomy and 6.5% (355) underwent wedge resection. Lobectomy was associated with improved OS compared with wedge resection for patients with occult pN1 disease (median OS, 70.0 months [95% CI, 66.6-77.4] vs 36.4 months [95% CI, 24.2-45.6]; P < .001) but not for pN2 disease (median OS, 48.2.1 months [95% CI, 43.8-52.9] vs 43.7 months [95% CI, 31.2-62.4]; P = 0.24). On inverse probability treatment weighting-adjusted multivariable analysis, adjusting for demographics, comorbidities, margin status, and pathologic T and N stage, lobectomy remained associated with improved survival (adjusted hazard ratio, 0.73; 95% CI, 0.60-0.89; P = .0016). CONCLUSIONS: Lobectomy is associated with improved survival in clinical stage Ia non-small cell lung cancer patients with occult lymph node disease. These data may aid the decision for completion lobectomy for patients with unanticipated N1 lymph node upstaging.
引用
- Kneuertz PJ, Abdel-Rasoul M, D'Souza DM, et al. Wedge Resection vs Lobectomy for Clinical Stage IA Non-Small Cell Lung Cancer With Occult Lymph Node Disease. Ann Thorac Surg. 2022. PMID: 36126718. doi:10.1016/j.athoracsur.2022.08.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。